Treatment of acute vivax malaria with tafenoquine


Autoria(s): Nasveld, Peter; Kitchener, Scott
Contribuinte(s)

Harold Townson

Data(s)

01/01/2005

Resumo

Tafenoquine is an 8-aminoquiniline related to primaquine with preclinical activity against a range of malaria species. We treated two acute cases of vivax malaria with tafenoquine (800 mg over three days) atone, instead of conventional chloroquine (1500 mg over three days) and primaquine (420 mg over 14 days). In addition to the convenience of this regimen, the rapid parasite clearances observed, coupled with a good clinical response and lack of recrudescence or relapse, indicate that further investigation of tafenoquine in the treatment of vivax malaria is warranted. (C) 2004 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

Identificador

http://espace.library.uq.edu.au/view/UQ:77206

Idioma(s)

eng

Publicador

Elsevier Ltd

Palavras-Chave #Public, Environmental & Occupational Health #Tropical Medicine #Malaria #Plasmodium Vivax #Tafenoquine #Papua New Guinea #Chloroquine-resistant Strain #Plasmodium-vivax #Wr 238605 #Blood #Wr238605 #Efficacy #Safety #CX #321208 Primary Health Care #730299 Public health not elsewhere classified
Tipo

Journal Article